Maze Therapeutics (NASDAQ:MAZE) Releases Earnings Results, Beats Expectations By $0.08 EPS

by · The Cerbat Gem

Maze Therapeutics (NASDAQ:MAZE – Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.66) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08, Zacks reports.

Maze Therapeutics Stock Down 2.1%

Shares of NASDAQ:MAZE traded down $0.64 during trading on Thursday, reaching $29.63. The stock had a trading volume of 276,063 shares, compared to its average volume of 322,400. Maze Therapeutics has a one year low of $6.71 and a one year high of $34.29. The firm’s 50-day simple moving average is $25.26 and its 200 day simple moving average is $16.98.

Analyst Ratings Changes

MAZE has been the subject of a number of research reports. JPMorgan Chase & Co. upped their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a research report on Monday, September 29th. Wall Street Zen upgraded shares of Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Weiss Ratings reiterated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Maze Therapeutics in a research report on Thursday, September 18th. Finally, BTIG Research increased their price objective on shares of Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a research report on Friday, September 12th. Two equities research analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, Maze Therapeutics has an average rating of “Buy” and an average price target of $33.83.

Get Our Latest Stock Report on Maze Therapeutics

Insider Buying and Selling at Maze Therapeutics

In related news, Director Richard H. Scheller sold 20,744 shares of Maze Therapeutics stock in a transaction that occurred on Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Hedge Funds Weigh In On Maze Therapeutics

Several institutional investors have recently made changes to their positions in the company. Legal & General Group Plc lifted its position in Maze Therapeutics by 387.0% in the second quarter. Legal & General Group Plc now owns 4,242 shares of the company’s stock valued at $52,000 after buying an additional 3,371 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in Maze Therapeutics in the first quarter valued at about $57,000. Tower Research Capital LLC TRC lifted its position in Maze Therapeutics by 452.5% in the second quarter. Tower Research Capital LLC TRC now owns 4,608 shares of the company’s stock valued at $57,000 after buying an additional 3,774 shares during the last quarter. Bank of America Corp DE lifted its position in Maze Therapeutics by 33.6% in the second quarter. Bank of America Corp DE now owns 5,782 shares of the company’s stock valued at $71,000 after buying an additional 1,455 shares during the last quarter. Finally, Rhumbline Advisers acquired a new position in Maze Therapeutics in the first quarter valued at about $80,000.

Maze Therapeutics Company Profile

(Get Free Report)

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.

Featured Articles